FIRAZYR (icatibant)

High clinical benefit in their respective indications, but no demonstrated clinical advantage, with the exception of BERINERT in adults, adolescents and children, and FIRAZYR in adults, representing a moderate clinical added value for the management of acute hereditary angioedema attacks.

• BERINERT, CINRYZE, FIRAZYR and RUCONEST have been granted an MA for the treatment of acute hereditary angioedema attacks (HAE) and/or for short-term and/or long-term prevention in children, adolescents and adults, according to their respective MAs.

• Subcutaneous administration of FIRAZYR, with self-administration by the patient possible after learning, presents a benefit relative to IV administration, particularly when used in an emergency context. Its short plasma half-life may require a second injection. BERINERT and CINRYZE, administered IV, have longer half-lives, respectively of 36 and 56 h, than those of FIRAZYR and RUCONEST.

• RUCONEST may contain traces of rabbit protein, thus requiring precautions prior to its use, though it is administered in an emergency context.